Background
Severe acute respiratory syndrome coronavirus 2 has had devastating effect on access to care in many specialties and dental services including oral medicine. Following the shelter‐in‐place orders in March 2020, we implemented Tele(oral)medicine practices for the diagnosis and management of some oral medicine conditions.
Objectives
To assess the role of telemedicine visits with respect to managing pain among patients affected by oral diseases.
Methods
A retrospective chart review for all the new patients seen at their first visit via telemedicine between April 2020 and December 2020. The patient-reported pain score was recorded at each visit using a 0–10 scale. Differences in oral pain from the first fist to the follow-up visit of the patients were evaluated using the Wilcoxon signed-rank test.
Results
A total of 137 new patients were included with a median age of 56 years. If seen in person, patients would have travelled a median distance of 65 miles. The most common oral conditions seen were reactive/inflammatory lesions. There was a 3-point median pain reduction from the first video visit to the first follow-up (p < 0.05) and a self-reported 65% median improvement of oral symptoms.
Conclusion
Tele(oral)medicine was an effective method for symptoms management of oral medicine conditions.
Background
Delusional infestation (DI) is a rare psychotic disorder characterized by a patient’s false belief that the body is infested with living or non-living organisms in the absence of clinical evidence of disease. Based on the underlying etiology, DI can be classified into primary and secondary forms based on the presence or absence of an underlying condition or previously diagnosed psychiatric disorder. This paper discusses a condition that is not commonly reported in the literature.
Case presentation
Here, we describe four patients diagnosed with DI of the oral cavity. In each case, the patients’ intraoral examinations revealed either traumatic lesions or no signs of mucosal disease. Management involved symptom management, medical therapy, and/or a referral to the primary care provider.
Conclusion
Because oral health care providers may encounter patients with DI, they should familiarize themselves with this unusual condition in order to recognize the condition and initiate prompt referral to a psychiatrist.
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had devastating effect on access to care in many specialties and dental services including oral medicine. Following the shelter‐in‐place orders in March 2020, we implemented Tele(oral)medicine practices for the diagnosis and management of some oral medicine conditionsObjectives: To assess the effectiveness of telemedicine visits with respect to pain control among patients affected by oral diseases. Methods: A retrospective chart review for all the new patients seen at their first visit via telemedicine between April 2020 and December 2020. The patient-reported pain score was recorded at each visit using a 0-10 scale. Differences in oral pain from the first fist to the follow-up visit of the patients were evaluated using the Wilcoxon signed-rank test. Results: A total of 137 new patients were included with a median age of 56 years. If seen in person, patients would have travelled a median distance of 65 miles. The most common oral conditions seen were reactive/inflammatory lesions. There was a 3-point median pain reduction from the first video visit to the first follow-up (p<0.05) and a self-reported 65% median improvement of oral symptoms. Conclusion: Tele(oral)medicine was an effective method for symptoms management of oral medicine conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.